That’s right. The antipsychotic, as you know, can cause weight gain and diabetes. And a survey conducted last month finds that 86 percent of psychiatrists are now writing fewer scrips for Zyprexa. They cited the side effects as the reason, according to Sandra Chow, an analyst at Decision Resources, the market-research firm that queried 151 docs.
“Zyprexa, you know, dominated the schizophrenia market just two years ago. In fact, Zyprexa was the number one choice for first-line, second-line and third-line treatment a couple of years ago,” Chow tells Pharmalot. “But the side effects have really changed the perception.”
The fall from grace follows a year in which litigation documents were leaked indicating Lilly allegedly hid side-effect data from docs, and several states filed suit against the drugmaker for improperly marketing the medication.
And which drugs are picking up market share? Bristol-Myers Squibb’s Abilify gained the most, followed by Pfizer’s Geodon, says Chow. However, Johnson & Johnson’s Risperdal and AstraZeneca’s Seroquel also benefited at Lilly’s expense, and are now the leaders as first-line treatments. Zyprexa, Chow notes, has dropped to fourth place among the antipsychotics.